绥美凯（Inbec）中文版说明书

Common name: Inbec

Product name: Suimeikai

All names: Suimeike, Dotiabalamid tablets, TRIUMEQ, Inbec

Suimeikai (Inbec) indications: Suitable for the treatment of adults and adolescents over 12 years old (weight at least 40kg) infected with human immunodeficiency virus (HIV). 

Inbec dosage: Adults and adolescents (weighing at least 40kg). For adults and adolescents, the recommended dosage of Inbec is one tablet, once a day. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. 

Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. 

If the patient misses a dose of Suimei Kai and there are more than 4 hours before the next dose, Sui Meikai should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. 

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group. 

Adverse reactions of Inbec:

Clinical data on Trimax are limited, and the most commonly reported adverse reactions that are possibly or probably related to dolutegravir and abacalongvir/lamivudine are nausea (12%), insomnia (7%), dizziness (6%), and headache (6%).